48,830
edits
(→Techniques: more) |
|||
Line 64: | Line 64: | ||
**Receptors in breast cancer (ER, PR, HER2). | **Receptors in breast cancer (ER, PR, HER2). | ||
**Lung cancer biomarkers ([[Lung_carcinoma_with_EGFR_mutation|EGFR]], [[Lung carcinoma with ALK rearrangement|ALK]], PD-L1, [[ROS1-rearranged non-small cell lung carcinoma|ROS1]]). | **Lung cancer biomarkers ([[Lung_carcinoma_with_EGFR_mutation|EGFR]], [[Lung carcinoma with ALK rearrangement|ALK]], PD-L1, [[ROS1-rearranged non-small cell lung carcinoma|ROS1]]). | ||
**BRAF testing in malignant melanoma. | **BRAF testing in [[malignant melanoma]]. | ||
**[[Microsatellite instability in colorectal cancer|MSI testing]] in colorectal cancer. | **[[Microsatellite instability in colorectal cancer|MSI testing]] in [[colorectal cancer]]. | ||
==See also== | ==See also== |
edits